La Jolla Pharmaceutical (NASDAQ:LJPC) COO Jennifer Carver purchased 5,000 shares of the firm’s stock in a transaction on Wednesday, January 9th. The shares were acquired at an average cost of $6.17 per share, for a total transaction of $30,850.00. Following the completion of the acquisition, the chief operating officer now owns 7,632 shares of the company’s stock, valued at $47,089.44. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

LJPC opened at $6.10 on Friday. The stock has a market capitalization of $159.76 million, a P/E ratio of -1.13 and a beta of 1.72. La Jolla Pharmaceutical has a 12 month low of $5.01 and a 12 month high of $41.36.

La Jolla Pharmaceutical (NASDAQ:LJPC) last released its quarterly earnings results on Wednesday, October 24th. The biopharmaceutical company reported ($1.93) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($2.01) by $0.08. The company had revenue of $3.47 million during the quarter, compared to analysts’ expectations of $3.38 million. As a group, analysts expect that La Jolla Pharmaceutical will post -8 EPS for the current year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in LJPC. Scopia Capital Management LP boosted its position in shares of La Jolla Pharmaceutical by 346.8% during the second quarter. Scopia Capital Management LP now owns 2,583,170 shares of the biopharmaceutical company’s stock valued at $75,351,000 after buying an additional 2,005,025 shares during the period. Point72 Asset Management L.P. purchased a new position in shares of La Jolla Pharmaceutical during the third quarter valued at approximately $21,014,000. BlackRock Inc. boosted its position in shares of La Jolla Pharmaceutical by 24.8% during the second quarter. BlackRock Inc. now owns 1,454,127 shares of the biopharmaceutical company’s stock valued at $42,417,000 after buying an additional 288,994 shares during the period. FMR LLC boosted its position in shares of La Jolla Pharmaceutical by 7.5% during the third quarter. FMR LLC now owns 3,933,641 shares of the biopharmaceutical company’s stock valued at $79,184,000 after buying an additional 275,957 shares during the period. Finally, Pictet Asset Management Ltd. boosted its position in shares of La Jolla Pharmaceutical by 12.9% during the third quarter. Pictet Asset Management Ltd. now owns 1,066,021 shares of the biopharmaceutical company’s stock valued at $21,459,000 after buying an additional 121,594 shares during the period.

A number of equities research analysts have commented on LJPC shares. BidaskClub cut La Jolla Pharmaceutical from a “sell” rating to a “strong sell” rating in a report on Tuesday, October 9th. Zacks Investment Research raised La Jolla Pharmaceutical from a “sell” rating to a “hold” rating in a report on Thursday, September 27th. ValuEngine cut La Jolla Pharmaceutical from a “buy” rating to a “hold” rating in a report on Tuesday, October 2nd. Finally, HC Wainwright reissued a “buy” rating and set a $48.00 price target on shares of La Jolla Pharmaceutical in a report on Thursday, October 25th. Five research analysts have rated the stock with a sell rating and three have issued a buy rating to the company’s stock. La Jolla Pharmaceutical has a consensus rating of “Hold” and an average target price of $39.67.

TRADEMARK VIOLATION WARNING: “Jennifer Carver Buys 5,000 Shares of La Jolla Pharmaceutical (LJPC) Stock” was reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this article on another domain, it was illegally copied and republished in violation of international copyright legislation. The correct version of this article can be accessed at https://theolympiareport.com/2019/01/11/jennifer-carver-buys-5000-shares-of-la-jolla-pharmaceutical-ljpc-stock.html.

About La Jolla Pharmaceutical

La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. It offers GIAPREZA, an injection for intravenous infusion indicated to increase blood pressure in adults with septic or other distributive shock.

Further Reading: Day Trading – Risk Worth the Reward?

Insider Buying and Selling by Quarter for La Jolla Pharmaceutical (NASDAQ:LJPC)

Receive News & Ratings for La Jolla Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.